Fasciolicides: efficacy, actions, resistance and its management.
about
Activity of OZ78 analogues against Fasciola hepatica and Echinostoma caproniFascioliasis: An Ongoing Zoonotic Trematode InfectionDrug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screeningPhysiological and morphological effects of genistein against the liver fluke, Fasciola hepaticaScreen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signalingThe small molecule triclabendazole decreases the intracellular level of cyclic AMP and increases resistance to stress in Saccharomyces cerevisiaeFascioliasis and intestinal parasitoses affecting schoolchildren in Atlixco, Puebla State, Mexico: epidemiology and treatment with nitazoxanideFasciolosis in South America: epidemiology and control challenges.Triclabendazole protects yeast and mammalian cells from oxidative stress: identification of a potential neuroprotective compoundIn vivo and in vitro sensitivity of Fasciola hepatica to triclabendazole combined with artesunate, artemether, or OZ78Integrating fasciolosis control in the dry cow management: the effect of closantel treatment on milk production.Fasciola hepatica vaccine: we may not be there yet but we're on the right roadDiagnosis of human fascioliasis in Arusha region, northern Tanzania by microscopy and clinical manifestations in patients.Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signalingExtracellular pH Modulates Neuroendocrine Prostate Cancer Cell Metabolism and Susceptibility to the Mitochondrial Inhibitor Niclosamide.The anthelmintic triclabendazole and its metabolites inhibit the membrane transporter ABCG2/BCRPAnthelmintic Potential of Thymoquinone and Curcumin on Fasciola gigantica.Triclabendazole for the treatment of fascioliasis and paragonimiasis.In vitro tegumental alterations on adult Fasciola gigantica caused by mefloquine.Anthelmintics Resistance; How to Overcome it?Prevalence of gastrointestinal nematodes and Fasciola hepatica in sheep in the northwest of Spain: relation to climatic conditions and/or man-made environmental modifications.Pharmacokinetics of the fasciocidal drug candidates MT04 and OZ78 in uninfected rats and in vitro pharmacodynamic studies.Triclabendazole progress report, 2005-2009: an advancement of learning?Transcriptomic responses of water buffalo liver to infection with the digenetic fluke Fasciola gigantica.Recent advances in the diagnosis, impact on production and prediction of Fasciola hepatica in cattle.Assessment of flukicide efficacy against Fasciola hepatica in sheep in Sweden in the absence of a standardised test.Juvenile-specific cathepsin proteases in Fasciola spp.: their characteristics and vaccine efficacies.A review of bovine fasciolosis and other trematode infections in Nigeria.Development of Fasciola Vaccine in an Animal Model.Development and validation of a liquid chromatography and ion spray tandem mass spectrometry method for the quantification of artesunate, artemether and their major metabolites dihydroartemisinin and dihydroartemisinin-glucuronide in sheep plasma.Niclosamide: Beyond an antihelminthic drug.In vitro ovicidal activity of Peganum harmala seeds extract on the eggs of Fasciola hepatica.Ovicidal effect of the methanolic extract of ginger (Zingiber officinale) on Fasciola hepatica eggs: an in vitro study.Use of bait containing triclabendazole against Fasciola gigantica in a herd of captive wild impala (Aepyceros melampus).First report of closantel treatment failure against Fasciola hepatica in cattleIn vitro efficacy of triclabendazole and clorsulon against the larval stage of Echinococcus multilocularis.Ultrastructural changes to the tegumental system and the gastrodermal cells in adult Fasciola hepatica following in vivo treatment with the experimental fasciolicide, compound alpha.Pleiotropic alterations in gene expression in Latin American Fasciola hepatica isolates with different susceptibility to drugs.Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasis.Closantel nano-encapsulated polyvinyl alcohol (PVA) solutions.
P2860
Q24630199-7AE52ADF-FD15-4F6C-97E3-A9F670DB7C92Q26784560-EE5843F6-2676-4DD3-9A53-38A880523431Q27306843-3081ADE7-2C20-4D1B-94F2-3ECBD4CCF559Q28292996-D157D701-8360-4EAE-98D3-2D151555E5C3Q28476186-FF1298C8-2984-4E19-BF7D-D080D702BE70Q28487770-CA0F54D2-1925-47E5-8EB1-E47DF8515BB6Q28535341-4C2C96C5-4B14-4A65-981F-1D32C7F6D0EEQ30245533-C7CB1CCC-93C6-45FB-8A8C-9123205C3FDFQ34030165-DCC57142-A020-43CA-99E8-EF412EAEAF95Q34290075-97BDB386-0CA0-495B-95C4-6936FF377411Q34391418-2A368E70-D7D4-4A70-913F-0FC490B03A17Q35195502-863F35BA-0688-4772-AB98-62493E012272Q35876011-7FC238A2-8AF1-4654-8451-98F3A56B10B3Q36006981-12C91D30-E6E7-4845-9B33-F232E8B4F5FFQ36083012-4D0775F4-3AB9-4B74-A834-830A7422F42AQ36086400-70C1FBB7-7590-461E-8F1F-2B4B1F683A83Q36267982-7AC9B341-5B80-4CED-9EE8-FB61CFDEBCAAQ36322074-D9C29BEE-E609-4592-B823-8BC8361E7D09Q36750810-E576C89C-F1EB-4C6A-B7EE-524D1785BFC2Q36847608-5A75E50E-5D66-42AA-8EBD-E567564C3205Q37361449-7FA6FA3F-AC1B-4EE8-ADCF-3E3A1C236B9BQ37390557-9F179A1A-26EE-4A6E-9BD2-6C1BA49A44C1Q37444251-47DE8B09-AEAC-429B-BFE2-02E6DC7584BAQ37618742-A89A009A-4EFB-43FE-B6A8-3858A4780CADQ38162536-C4066022-C3BE-4187-93E6-E6D03F407E16Q38408628-E288B419-852E-48F8-8299-5DF72A811F0CQ38534374-1D11F86F-48E4-4C6F-A749-BB45612BB3D3Q38681362-E38425B2-E145-401C-92D6-AA096DB6E75AQ38881498-CE5D4B91-6D4E-4BF5-A932-C961380CD4F1Q38980419-DC81FAC7-0143-42FB-AC00-6A34432DB180Q39227540-96AC5B8D-1690-4889-90B2-F90B393BA7A4Q40171999-D70FB17C-79B7-4046-A6CE-7AC9ECB7DBE5Q40548137-C6D84D39-8A08-4574-815F-67B393995EA8Q40659686-A476880E-984B-45EB-B3AC-B9F36ADECB50Q40961220-34B72EFD-B004-4414-97E5-3163A63D01D3Q42272747-2350B5EF-E695-4199-A0D9-8E83F8D5786BQ46050145-7B8771BB-F40C-4A09-A05F-429C310A2268Q49197054-B44103D4-5A69-4D44-B042-0B057EEFDAAFQ51124579-F3C7B8FC-368C-444A-A954-0E6F429B24F5Q52663227-DA8C9FDC-C536-425F-B034-2642F206E663
P2860
Fasciolicides: efficacy, actions, resistance and its management.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Fasciolicides: efficacy, actions, resistance and its management.
@ast
Fasciolicides: efficacy, actions, resistance and its management.
@en
type
label
Fasciolicides: efficacy, actions, resistance and its management.
@ast
Fasciolicides: efficacy, actions, resistance and its management.
@en
prefLabel
Fasciolicides: efficacy, actions, resistance and its management.
@ast
Fasciolicides: efficacy, actions, resistance and its management.
@en
P356
P1476
Fasciolicides: efficacy, actions, resistance and its management.
@en
P2093
Fairweather I
P304
P356
10.1053/TVJL.1999.0377
P577
1999-09-01T00:00:00Z